Scarica l'app Stockscreener
6.82
3.81%
-0.27
Pre-mercato:
6.66
-0.16
-2.35%
Precedente Chiudi:
$7.09
Aprire:
$6.9
Volume 24 ore:
105.49K
Relative Volume:
0.49
Capitalizzazione di mercato:
$432.27M
Reddito:
-
Utile/perdita netta:
$-159.39M
Rapporto P/E:
-1.9265
EPS:
-3.5401
Flusso di cassa netto:
$-105.22M
1 W Prestazione:
-3.40%
1M Prestazione:
-11.31%
6M Prestazione:
-41.21%
1 anno Prestazione:
-53.89%
Intervallo 1D:
$6.52
$6.99
Intervallo di 1 settimana:
$6.52
$7.85
Portata 52W:
$5.495
$16.63
Abivax Adr Stock (ABVX) Company Profile
Confronta ABVX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
6.82 | 432.27M | 0 | -159.39M | -105.22M | -3.5401 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.55 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.83 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
593.47 | 36.20B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.02 | 35.08B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
262.60 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-20 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-12-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-29 | Iniziato | Laidlaw | Buy |
| 2024-05-20 | Iniziato | BTIG Research | Buy |
| 2024-04-29 | Iniziato | Guggenheim | Buy |
| 2024-04-29 | Iniziato | Piper Sandler | Overweight |
| 2023-11-14 | Iniziato | Leerink Partners | Outperform |
| 2023-11-14 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Abivax Adr Borsa (ABVX) Ultime notizie
Abivax SA: Promising Clinical Developments and Positive Outlook Justify Buy Rating - TipRanks
Promising Prospects for Abivax: Buy Rating Backed by Clinical Progress and Financial Strength - TipRanks
Abivax SA’s Obefazimod: A Promising Blockbuster in Ulcerative Colitis Treatment - TipRanks
Positive Outlook for Abivax: Buy Rating Supported by Promising Phase 3 Trials and Strong Financial Position - TipRanks
Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025 - TipRanks
Buy Rating for Abivax: Promising Potential of Obefazimod in Ulcerative Colitis Treatment - TipRanks
Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High? - MSN
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year? - Nasdaq
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 - GlobeNewswire Inc.
Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet - Yahoo Finance
Potential Price Increase for Abivax ADR (ABVX) After Recent Insider Activity - Knox Daily
Sibanye Stillwater Limited ADR (SBSW) rating downgrades by HSBC Securities - Knox Daily
Quantum Corp (QMCO) Stock: A Closer Look at the Market Potential - The News Heater
Analyzing the Price-to-Earnings Ratio of Abivax ADR (ABVX) - The News Heater
Capricor Therapeutics Inc (CAPR) Shares Plummet Below 1-Year High - The News Heater
Paylocity Holding Corp’s (PCTY) Stock: A Long-Term Performance Analysis - The News Heater
Perrigo Company plc (PRGO) Stock: A Closer Look at the Moving Averages - The News Heater
Analyzing the Price-to-Earnings Ratio of ICL Group Ltd (ICL) - The News Heater
Tectonic Therapeutic Inc (TECX) Stock: A Review of the Recent Movement - The News Heater
Healthcare Triangle Inc (HCTI) Stock: A Closer Look at the Market Potential - The News Heater
Here's Why Abivax SA Sponsored ADR (ABVX) is Poised for a Turnaround After Losing -19.81% in 4 Weeks - MSN
Abivax Initiates $150 Million ATM Program on Nasdaq - TipRanks
Abivax Reports Strong Q3 Financials and Clinical Progress - TipRanks
Check Out Abivax ADR (ABVX)’s Trade Data Rather Than the Analysts’ Views - SETE News
Insider’s View: Deciphering Abivax ADR (ABVX)’s Financial Health Through Ratios - The Dwinnex
Abivax SA Unveils New Ulcerative Colitis Treatment Data - TipRanks
Abivax Reports Progress in Ulcerative Colitis Therapy - TipRanks
Is Abivax SA Sponsored ADR (ABVX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Wall Street Analysts Believe Abivax SA Sponsored ADR (ABVX) Could Rally 193.62%: Here's is How to Trade - Yahoo Finance
Abivax SA Details Financial Struggles and Advances - TipRanks
Abivax SA Reveals Soaring R&D Costs in H1 2024 - TipRanks
Abivax ADR receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Citi Appointed as Depositary Bank for Abivax SA’s ADR Program - Business Wire
Abivax Adr Azioni (ABVX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.46%
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):